Celcuity Inc. Share Price & Technical Analysis
CELC · $89.49 (+1.42%)
Healthcare / Biotechnology
$89.49
+1.42%
Celcuity Inc., a clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's lead drug candidate includes Gedatolisib, which selectively targets various Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2 …
Price chart
Seasonality
Jun has 4 positive and 1 negative years (last 5 years shown)
-32% return in Jun, 10% avg return in past 3 year Jun month.
1% return in 2026, 113% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | 10% | 5% | 3% | 5% | 10% | -32% | – | – | – | – | – | – | 1% |
| 25 | -10% | -19% | 7% | 11% | -4% | 25% | 188% | 33% | -3% | 57% | 32% | 0% | 318% |
| 24 | 4% | 3% | 39% | -28% | 0% | 3% | 11% | -13% | -6% | 4% | -18% | 2% | 1% |
| 23 | -31% | 24% | -14% | 2% | 5% | 2% | -10% | -4% | -5% | 14% | 37% | 0% | 20% |
| 22 | -15% | -10% | -8% | -30% | 0% | 36% | 0% | 3% | 6% | -2% | -9% | 57% | 29% |
Monthly return % by calendar month · historical pattern, not a forecast
Bearish · Downtrend · Weak
Celcuity Inc., a clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's lead drug candidate includes Gedatolisib, which selectively targets various Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2 to treat patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) or HR+/HER2-, advanced or metastatic breast cancer (ABC), and patients with metastatic castration resistant prostate cancer (mCRPC). The company had a license agreement with Pfizer Inc. for the development and commercialization rights to Gedatolisib. Celcuity Inc. was incorporated in 2011 and is based in Minneapolis, Minnesota.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$4.38B
P/E ratio
—
52W high
$151.0
52W low
$11.28
Volume
12,13,127
Beta
0.12
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹35,920
Abbott Laboratories Cede…
₹33,540
Eli Lilly And Company Ce…
₹30,700
Unitedhealth Group Inc C…
₹18,590
₹7,059
Frequently asked questions
- What is Celcuity Inc. share price today?
- Celcuity Inc. (CELC) last traded around $89.49 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does CELC have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for CELC. Download the app for real-time alerts.
- How can I analyze Celcuity Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.